The Predictive Value of Glucagon-Like Peptide 1 Plasma Levels on Acute Heart Failure
DOI:
https://doi.org/10.24293/ijcpml.v28i2.1838Keywords:
Acute heart failure, acute myocardial infarct, glucagon-like peptide-1Abstract
Acute Heart Failure (AHF) is one of the mechanical complications of Acute Myocardial Infarct (AMI). The diagnostic approach of AHF caused by AMI is based on clinical score, imaging, use of invasive instruments, and laboratory parameters. Glucagon-Like Peptide-I (GLP-1) is an incretin hormone derivate of proglucagon gene transcription, secreted by the L cells from the mucosa of the ileum, colon, and rectum. The cardioprotective effect of GLP-1 through the dependent and independent pathway produces a direct and indirect cardiovascular effect that increases the functional capacity in AHF patients. This study aims to find the predictive value of plasma GLP-1 towards the incidence of AHF in patients with AMI. This study was conducted on 35 patients diagnosed with AMI at Dr. Moewardi General Hospital Surakarta, in October-December 2020. Glucagon-like peptide-I was measured using the ELISA sandwich. The cut-off of plasma GLP-1 was determined using the Receiver Operating Characteristic (ROC) curve. Statistical analysis showed an RR (95% CI) of 2.292 (0.587–8.943) with a p=0.229 for age, 1,143 (0.299–4.367) with a p – 0.127 for a history of type 2 diabetes (T2DM) and plasma GLP-1 concentrations below Cut-Off Value (COV), which was 2.881 (0.729–11.381) with p=0.127. Age, a history of T2DM, and plasma GLP-1 below COV did not significantly affect AHF complications in patients with AMI.
Downloads
References
Baransyah L, Rohman MS, Suharsono T. Faktor-faktor yang berpengaruh terhadap kejadian gagal jantung pada pasien infark miokard akut di Rumah Sakit Dr. Saiful Anwar Malang. MK-FKUB, 2014; 1(4): 209-13.
Sulo G, Vollset SE, Nygard O, Ebbiry M, Sule E, Egeland DM. Heart failure complication acute myocardial infarction; Burden and timing of occurrence: A nation- wide analysis including 86771 patients from the cardiovascular disease in Norway (CVDNOT) project. J Am Heart Assoc, 2016; 5(1):1-8.
Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanism incidence and identification of patients out risk. World J Cardiol, 2017; 9(5): 407-15.
Taguchi E, Konami Y, Inoue M, Suzuyama H, Kodema K, Yoshida M, Miyamoto S, et al. Impact of KILLIP classification on acute myocardial infarction: Data from the SAIKUMA registry. Heart and Vessels, 2017; 32(1):1439-47.
Bahit MC, Kocher MD, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail, 2018; 6(3):179-86.
Coats AJS. Common comorbidities in heart failure-diabetes, functional mitral regurgitation and sleep apnoe. Int J Heart Failur, 2019; 1(1): 25-41.
Garcia MI, Torres JFM. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res, 2018;1(2): 1-12.
Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol, 2019; 60(1): 347-51.
Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy review of head to head clinical trials. Front Endocrinol, 2020; 11(178):1-13.
Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab, 2017; 43(12): 14-19.
Zykov VA, Tuchina TP, Lebedev DA, Krylova IB, Babenko AY, et al. Effect of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus. World J Diabetes, 2018; 9(9):149-56.
Gerber Y, Weston SA, Sarano ME, Berardi C, Chamberlain AM, et al. Mortality associated with heart failure after myocardial infarction. Circ Heart Fail, 2016; 9(1): 1-9.
Waty M, Hasan H. Prevalensi penyakit jantung hipertensi pada pasien gagal jantung kongestif di RSUP H. Adam Malik. E-Journal FK USU, 2013;1(1):1-9.
Rahayu MS. Hubungan indeks massa tubuh dengan penyakit jantung koroner di Rumah Sakit Umum Cut Meutia Kabupaten Aceh Utara. MJMA, 2015 ;6(1): 9-16.
Nursalim A, Yuniadi Y. Paradox obesitas pada pasien gagal jantung. J Kardiol Indones, 2011; 32(1): 207-8.
Simonenko M. Obesity paradox in heart failure: A matter of debate. Eur J Prev Cardiol, 2019; 1(1):1-3.
Wellings J, Kostis JB, Sargsyan D, Kostis WJ, Cabrera J. Risk factors and trends in incidence of heart failure following acute myocardial infarction. Am J Cardiol, 2018; 1(2):1-15.
Gennaro LD, Brunetti ND, Correole M, Buquicchio F, Caldarola P, Biase MD. Statin therapy in heart failure: For good, for bad, or indifferent?. Curr Atheroscler Rep, 2014;16(377):1-8.
Hedayatnia M, Asadi Z, Feyzabadi RZ, Kharasani MY, Ghazizade H, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis, 2020;19(42): 1-11.
Iskandar, Hadi A, Alfridsyah. Faktor risiko terjadinya penyakit jantung koroner pada pasien Rumah Sakit Umum Meuraxa Banda Aceh. Action Journal, 2017; 2(1): 32-42.
Ahmed AA, Patel K, Nyaku MA, Kheirbek RE, Bittner V, et al. 2015. Risk of heart failure and death after prolonged smoking cessation role of amount and duration of prior smoking. Circ Heart Fail, 2015; 8(1): 694-701.
Yudanardi MRR, Setiawan AA, Sofia SN. Hubungan tingkat adiksi merokok dengan derajat keparahan aterosklerosis pada pasien penyakit jantung koroner. J Kedokt Diponegoro, 2016; 5(4): 1207-13.
Dunlay SM, Givertz MM, Aguilar R, Allen LA, Chan M, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail, 2019; 25(8): 584-619.
Perry HM, Deshmukh H, Levin D, Zuydam NV, Elder DHJ, et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail, 2015; 8(1): 236-42.
Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1c and mortality in heart failure patients with diabetes. J Am Coll Cardiol, 2009; 54(5): 422-28.
Blecker S, Park H, Katz SD. Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovasc Disord, 2016; 16(99): 1-8.
Villanueva P, Alfonso F. Heart failure in the eldery. J Geriatr Cardiol, 2016;13(1): 115-17.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev, 2007; 87(1): 1409-39.
Thompson A, Kanamarlapudi V. Type 2 diabetes mellitus and glucagon like peptide-1 receptor signalling. Clin Exp Pharmacol, 2013; 3(138): 1-18.
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?. Diabetologia, 2011; 54(1):10-18.
Negard BJ, Lindgvist A, Gislason HG, Group L, Ekelund M, Wierup N, Hedenbro JL. Mucosal glucagon-like peptide-1 and gastric inhibitory polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis, 2015; 1(1):1-10.
Wang XC, Liu H, Chen J, Li Y, Qu S. Multiple factors related to the secretion of glucagon-like peptide-1. Int J Endocrinol, 2015; 1(2): 1-11.
Sheehan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J, 2019; 1(2): 1-6.
Li J, Zheng J, Wang S, Lau HK, Fathi A, Wang Q. Cardiovascular benefits of native GLP-1 and its metabolites: An indicator for GLP-1-therapy strategies. Front Physiol, 2017; 8(15): 1-13.
Arruda-Junior DF, Martins FL, Salles TA, Jensen L, Dariolli R, et al. Post-prandial increase in glucagon-like peptide 1 is blunted in severe heart failure. Clin Sci, 2020; 134(1): 1081-94.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
